ASPS
MCID: ALV005
MIFTS: 56

Alveolar Soft Part Sarcoma (ASPS)

Categories: Cancer diseases, Genetic diseases, Muscle diseases, Rare diseases

Aliases & Classifications for Alveolar Soft Part Sarcoma

MalaCards integrated aliases for Alveolar Soft Part Sarcoma:

Name: Alveolar Soft Part Sarcoma 57 12 75 53 59 37 29 15 17 72
Asps 57 53 59
Sarcoma, Alveolar Soft Part 44 40
Alveolar Soft-Part Sarcoma 57 13
Childhood Alveolar Soft-Part Sarcoma 72
Adult Alveolar Soft-Part Sarcoma 72
Alveolar Soft Tissue Sarcoma 59
Sarcoma Alveolar Soft Part 55

Characteristics:

Orphanet epidemiological data:

59
alveolar soft tissue sarcoma
Age of onset: All ages;

HPO:

32
alveolar soft part sarcoma:
Inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:4239
OMIM 57 606243
KEGG 37 H00051
MeSH 44 D018234
SNOMED-CT 68 88195001
MESH via Orphanet 45 D018234
ICD10 via Orphanet 34 C49.9
UMLS via Orphanet 73 C0206657
Orphanet 59 ORPHA163699
MedGen 42 C0206657
UMLS 72 C0206657 C0279544 C0279985

Summaries for Alveolar Soft Part Sarcoma

NIH Rare Diseases : 53 Alveolar soft part sarcoma (ASPS) is a rare, slow-growing soft tissue sarcoma. Although it has been described in a variety of locations, it most commonly develops on the lower extremities in adults and in the head and neck region of children. ASPS generally presents as a soft, pain-less lump that is often not associated with any additional signs and symptoms. In many cases, the condition is not diagnosed until the affected person develops symptoms of metastasis to other sites such as the lungs, bones, central nervous system and/or liver. The underlying cause of ASPS is poorly understood. Most cases occur sporadically in people with no family history of the condition. ASPS is generally treated with surgery; radiation therapy and/or chemotherapy may be considered if the tumor returns.

MalaCards based summary : Alveolar Soft Part Sarcoma, also known as asps, is related to spindle cell sarcoma and renal cell carcinoma, xp11-associated. An important gene associated with Alveolar Soft Part Sarcoma is ASPSCR1 (ASPSCR1 Tether For SLC2A4, UBX Domain Containing), and among its related pathways/superpathways are Transcriptional misregulation in cancer and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Penicillin G and Procaine have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and testes, and related phenotypes are alveolar soft part sarcoma and mortality/aging

Disease Ontology : 12 A soft tissue cancer that is a slow growing tumor of an unknown origin that effects children and effects young adults.

OMIM : 57 Alveolar soft part sarcoma is an unusual tumor with highly characteristic histopathology and ultrastructure, controversial histogenesis, and enigmatic clinical behavior (Lieberman et al., 1989; Ordonez, 1999). The typical histology of ASPS shows well-defined nests of cells with abundant pink cytoplasm. The loss of central cohesion produces a pseudoalveolar appearance (Ladanyi et al., 2001). (606243)

KEGG : 37
Alveolar soft part sarcoma (ASPS) is a rare, histologically distinctive soft-tissue sarcoma typically occurring in children and young adults. Although it displays a relatively indolent clinical course, the ultimate prognosis is poor and is often characterised by late metastases. ASPS is characterised by an unbalanced translocation: der(17)t(X:17)(p11;q25). This translocation causes the fusion of the TEF3 (transcription factor binding to IGHM enhancer 3) with a novel gene at 17q25, named ASPL. Translocation between chromosomes X and 17 is seen in all the tested cases, implicating transcriptional deregulation in the pathogenesis of this tumor.

Wikipedia : 75 Alveolar soft part sarcoma, abbreviated ASPS, is a very rare type of soft-tissue sarcoma, that grows... more...

Related Diseases for Alveolar Soft Part Sarcoma

Diseases related to Alveolar Soft Part Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 244)
# Related Disease Score Top Affiliating Genes
1 spindle cell sarcoma 32.3 VIM DES
2 renal cell carcinoma, xp11-associated 31.6 TFE3 ASPSCR1
3 granular cell tumor 31.3 VIM ENO2 DES
4 malignant mesenchymoma 31.0 MYOD1 MB DES
5 chordoma 30.8 VIM MET DES
6 perivascular epithelioid cell tumor 30.8 VIM SYP DES
7 rhabdomyosarcoma 2 30.5 MYOD1 MB ENO2 DES
8 leiomyosarcoma 30.3 VIM MB ENO2 DES
9 gastrointestinal stromal tumor 30.1 VIM SYP ENO2 DES
10 connective tissue benign neoplasm 29.9 SYP ENO2
11 rhabdomyosarcoma 29.5 VIM MYOD1 MYF6 MET MB ENO2
12 cervical alveolar soft part sarcoma 12.9
13 vulvar alveolar soft part sarcoma 12.9
14 soft tissue sarcoma 11.4
15 sarcoma 11.3
16 rare tumor 10.8
17 myofibroma 10.7 MB DES
18 giant cell myocarditis 10.7 MB DES
19 infantile digital fibromatosis 10.7 VIM DES
20 lymphangiomatosis 10.7 VIM DES
21 angiolipoma 10.7 VIM DES
22 syringocystadenoma papilliferum 10.7 VIM DES
23 parachordoma 10.7 VIM DES
24 spindle cell lipoma 10.7 VIM DES
25 gallbladder sarcoma 10.7 MYOD1 DES
26 breast rhabdomyosarcoma 10.7 MYOD1 MB
27 benign metastasizing leiomyoma 10.7 VIM DES
28 biphasic synovial sarcoma 10.7 VIM DES
29 renal cell carcinoma, nonpapillary 10.7
30 bilateral retinoblastoma 10.7 MB DES
31 rare soft tissue tumor 10.6
32 malignant ectomesenchymoma 10.6 ENO2 DES
33 ectomesenchymoma 10.6 ENO2 DES
34 malignant fibrous histiocytoma of bone 10.6 MYOD1 DES
35 bednar tumor 10.6 VIM ENO2
36 cystic nephroma 10.6 VIM DES
37 horner's syndrome 10.6 MYOD1 DES
38 syringoma 10.6 VIM DES
39 sertoli cell tumor 10.6 VIM SYP
40 pleomorphic rhabdomyosarcoma 10.6 MYOD1 MB
41 acral lentiginous melanoma 10.6 VIM MET
42 juvenile xanthogranuloma 10.6 VIM DES
43 kidney rhabdoid cancer 10.6 MB ENO2
44 primary hepatic neuroendocrine carcinoma 10.6 VIM SYP
45 doxorubicin induced cardiomyopathy 10.6 MET DES
46 ependymoblastoma 10.6 VIM MET
47 pleomorphic liposarcoma 10.6 VIM DES
48 chordoid meningioma 10.6 VIM SYP
49 adult fibrosarcoma 10.6 MYOD1 MB
50 congenital fibrosarcoma 10.6 VIM DES

Graphical network of the top 20 diseases related to Alveolar Soft Part Sarcoma:



Diseases related to Alveolar Soft Part Sarcoma

Symptoms & Phenotypes for Alveolar Soft Part Sarcoma

Human phenotypes related to Alveolar Soft Part Sarcoma:

32
# Description HPO Frequency HPO Source Accession
1 alveolar soft part sarcoma 32 HP:0012218

Clinical features from OMIM:

606243

MGI Mouse Phenotypes related to Alveolar Soft Part Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 mortality/aging MP:0010768 10.03 ADAM9 DES ECM1 MB MET MLH1
2 homeostasis/metabolism MP:0005376 10.02 ADAM9 DES MB MET MLH1 MYF6
3 neoplasm MP:0002006 9.63 ADAM9 MET MLH1 MYF6 MYOD1 TCF3
4 normal MP:0002873 9.5 ADAM9 MET MYF6 MYOD1 SYP TCF3
5 respiratory system MP:0005388 9.17 ENO2 MB MET MLH1 MYF6 MYOD1

Drugs & Therapeutics for Alveolar Soft Part Sarcoma

Drugs for Alveolar Soft Part Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
2
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
3 Anti-Bacterial Agents Phase 4
4 Anti-Infective Agents Phase 4
5 penicillins Phase 4
6 Floxacillin Phase 4
7 Penicillin G Procaine Phase 4
8 Penicillin G Benzathine Phase 4
9
Ifosfamide Approved Phase 3 3778-73-2 3690
10
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
11
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
12
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
13
Lenograstim Approved, Investigational Phase 3 135968-09-1
14
Epirubicin Approved Phase 3 56420-45-2 41867
15
Etoposide Approved Phase 3 33419-42-0 36462
16
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
17
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
18
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
19
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
20
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
21
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
22
Histamine Approved, Investigational Phase 3 51-45-6 774
23
Cyproheptadine Approved Phase 3 129-03-3 2913
24 Immunologic Factors Phase 3
25 Immunosuppressive Agents Phase 3
26
Isophosphamide mustard Phase 3 0
27 Tubulin Modulators Phase 3
28 Antineoplastic Agents, Phytogenic Phase 3
29 Etoposide phosphate Phase 3
30 Nucleic Acid Synthesis Inhibitors Phase 3
31 Antimitotic Agents Phase 3
32 Antirheumatic Agents Phase 3
33 Antibiotics, Antitubercular Phase 2, Phase 3
34 Neurotransmitter Agents Phase 3
35 Alkylating Agents Phase 2, Phase 3
36
Liposomal doxorubicin Phase 2, Phase 3 31703
37 Topoisomerase Inhibitors Phase 2, Phase 3
38 Antineoplastic Agents, Alkylating Phase 2, Phase 3
39 Gastrointestinal Agents Phase 3
40 Anti-Allergic Agents Phase 3
41 Serotonin Antagonists Phase 3
42 Histamine H1 Antagonists Phase 3
43 Histamine Antagonists Phase 3
44 Dermatologic Agents Phase 3
45 Serotonin Agents Phase 3
46
Histamine Phosphate Phase 3 51-74-1 65513
47 Antipruritics Phase 3
48
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
49
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
50
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Pilot Randomised Controlled Trial of Penicillin Versus Flucloxacillin for Definitive Treatment of Invasive Penicillin Susceptible Staphylococcus Aureus Not yet recruiting NCT03632642 Phase 4 Benzylpenicillin;Flucloxacillin
2 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Risk-Based Treatment for Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Randomised Trial of Post-Operative Radiotherapy Given to Adult Patients With Extremity Soft Tissue Sarcoma [VORTEX] Completed NCT00423618 Phase 3
5 A Phase III Randomized Study of Preoperative Radiation Plus Surgery Versus Surgery Alone for Patients With Retroperitoneal Sarcomas (RPS) Completed NCT00091351 Phase 3
6 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
7 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
8 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
9 A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
10 Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma. Active, not recruiting NCT02929394 Phase 3 Trabectedin
11 TRUSTS: A Phase IIB/III Multicenter Study Comparing the Efficacy of TRabectedin Administered as a 3-Hour or 24-Hour Infusion to Doxorubicin in Patients With Advanced or Metastatic Untreated Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
12 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
13 Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
14 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
15 Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Unknown status NCT01883518 Phase 1, Phase 2
16 A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas Completed NCT00112463 Phase 2 romidepsin
17 A Phase 2 Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors Completed NCT00557609 Phase 2 ARQ 197
18 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
19 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
20 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
21 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
22 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
23 A Phase II Study Of Perifosine (D-21266) In Patients With Previously Untreated Metastatic Or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
24 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
25 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
26 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
27 A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas. Completed NCT00642941 Phase 2 RG1507
28 Sarcoma Alliance for Research Through Collaboration (SARC) Multicenter Trial: A Phase II Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas Completed NCT00401388 Phase 2 Perifosine
29 An Open-label, Single-arm, Phase II Clinical Study of Anti-PD-1 Antibody GB226 in Treatment of Relapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma (ASPS) Recruiting NCT03623581 Phase 2
30 A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma Recruiting NCT03141684 Phase 2 Atezolizumab
31 A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression Recruiting NCT01391962 Phase 2 Cediranib;Sunitinib
32 Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
33 Preoperative Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Recruiting NCT03989596 Phase 2
34 A Phase II Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS) Active, not recruiting NCT01337401 Phase 2 Cediranib;Placebo
35 Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma Active, not recruiting NCT00942877 Phase 2 AZD2171
36 A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS) Active, not recruiting NCT02636725 Phase 2 Axitinib;Pembrolizumab
37 Cross-tumoral Phase 2 Clinical Trial Exploring Crizotinib (PF-02341066) in Patients With Advanced Tumors Induced by Causal Alterations of ALK and/or MET ("CREATE") Active, not recruiting NCT01524926 Phase 2 Crizotinib (PF-02341066)
38 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Active, not recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
39 A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma Terminated NCT02113826 Phase 2 Pazopanib
40 Phase II Study of Preoperative Intensity-Modulated Radiation Therapy for Soft-Tissue Sarcomas Terminated NCT00740597 Phase 2
41 Phase I Study To Determine The Safety Of Caelyx (Doxorubin HCI, Pegylated Liposomal) In Combination With Ifosfamide In Previously Untreated Adult Patients With Advanced And/Or Metastatic Soft Tissues Sarcomas Completed NCT00030784 Phase 1 ifosfamide;pegylated liposomal doxorubicin hydrochloride
42 Optimization of Enoxaparin Prophylaxis Using Real-time Anti-Factor Xa Levels in Major Reconstructive Surgery Patients Completed NCT02687204 Phase 1 Twice daily enoxaparin prophylaxis;Real time dose adjustment
43 A Phase I Trial of Vaccination With Autologous, Lethally Irradiated Tumor Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Granulocyte-Macrophage Colony Stimulating Factor in Pediatric and Adult Patients Active, not recruiting NCT00258687 Phase 1
44 A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies Active, not recruiting NCT02936102 Phase 1 FAZ053;PDR001
45 A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma Not yet recruiting NCT03880123 Phase 1 Selinexor;Ixazomib
46 Research Registry for Juvenile Arthritis Unknown status NCT00090571
47 Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development Completed NCT00340353
48 Observational - Potentially Actionable Mutations in Archived Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) Completed NCT01567046
49 Partnership to Enhance Antimicrobial Use in Resource-Limited Settings (PEARL): An Assessment of Need and Feasibility of Antimicrobial Stewardship Programs Completed NCT03382470
50 Social Mechanisms for Promoting Physical Activity in After School Programs for Underserved Middle School Youth: A Feasibility Trial Completed NCT03850821

Search NIH Clinical Center for Alveolar Soft Part Sarcoma

Cochrane evidence based reviews: sarcoma, alveolar soft part

Genetic Tests for Alveolar Soft Part Sarcoma

Genetic tests related to Alveolar Soft Part Sarcoma:

# Genetic test Affiliating Genes
1 Alveolar Soft Part Sarcoma 29 ASPSCR1

Anatomical Context for Alveolar Soft Part Sarcoma

MalaCards organs/tissues related to Alveolar Soft Part Sarcoma:

41
Bone, Lung, Testes, Liver, Tongue, Breast, Brain

Publications for Alveolar Soft Part Sarcoma

Articles related to Alveolar Soft Part Sarcoma:

(show top 50) (show all 1472)
# Title Authors PMID Year
1
The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. 38 8
11244503 2001
2
Chromosome rearrangement at 17q25 and xp11.2 in alveolar soft-part sarcoma: A case report and review of the literature. 38 8
10506710 1999
3
Alveolar soft part sarcoma: a review and update. 38 8
10342010 1999
4
Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. 38 8
2642727 1989
5
Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. 9 38
18176180 2008
6
Pediatric renal cell carcinomas with Xp11.2 rearrangements are immunoreactive for hMLH1 and hMSH2 proteins. 9 38
16328670 2005
7
TFE3 immunoreactivity in alveolar soft part sarcoma of the uterine cervix: case report. 9 38
15782069 2005
8
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. 9 38
15735860 2005
9
Alveolar soft part sarcoma on the glabella. 9 38
15081230 2004
10
Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. 9 38
12766578 2003
11
Alveolar soft part sarcoma--reciprocal translocation between chromosome 17q25 and Xp11. Report of a case with metastases at presentation and review of the literature. 9 38
12769020 2003
12
Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics. 9 38
11688574 2001
13
Immunohistochemical profile of myogenin and MyoD1 does not support skeletal muscle lineage in alveolar soft part sarcoma. 9 38
10383802 1999
14
[Alveolar soft part sarcoma: a clinicopathologic and immunohistochemical study of 13 cases]. 9 38
1452160 1992
15
MyoD1 protein expression in alveolar soft part sarcoma as confirmatory evidence of its skeletal muscle nature. 9 38
1656801 1991
16
Essential human resources for antimicrobial stewardship teams in Japan: Estimates from a nationwide survey conducted by the Japanese Society of Chemotherapy. 38
31182329 2019
17
Attitude of clinicians towards hospital-based antimicrobial stewardship programs: a multicenter cross-sectional study from Punjab, Pakistan. 38
31335228 2019
18
Clinical practice guidelines for creating an acute care hospital-based antimicrobial stewardship program: A systematic review. 38
30904370 2019
19
Challenges and opportunities for antimicrobial stewardship in resource-rich and resource-limited countries. 38
31282277 2019
20
Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values. 38
31307635 2019
21
The economic impact of antimicrobial stewardship programmes in hospitals: a systematic literature review. 38
30880265 2019
22
Second Reported Case of Pediatric Bladder Alveolar Soft Part Sarcoma as Secondary Malignancy After Prior Cytotoxic Chemotherapy. 38
30986487 2019
23
Genetic Diversity in Alveolar Soft Part Sarcoma: A Subset Contain Variant Fusion Genes, Highlighting Broader Molecular Kinship with Other MiT Family Tumors. 38
31433528 2019
24
Cefazolin Versus Anti-Staphylococcal Penicillins for the Treatment of Patients with Methicillin-Susceptible Staphylococcus aureus Infection: A Meta-Analysis with Trial Sequential Analysis. 38
31392580 2019
25
Customizing an Electronic Medical Record to Automate the Workflow and Tracking of an Antimicrobial Stewardship Program. 38
31375823 2019
26
Acanthopanax senticosus polysaccharide suppressing proliferation and metastasis of the human non-small cell lung cancer NCI-H520 cells is associated with Wnt/β-catenin signaling. 38
30943746 2019
27
Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice. 38
31160250 2019
28
Blockade of VEGFR and PD-L1 Inhibits Alveolar Soft-Part Sarcoma. 38
31101632 2019
29
Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. 38
30626710 2019
30
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. 38
31160249 2019
31
Lingual Alveolar Soft Part Sarcoma in a 1-Year-Old Infant: Youngest Reported Case With Characteristic ASPSCR1-TFE3 Fusion. 38
30744536 2019
32
An Investigation Into the Factor Structure of the Attitudes to Suicide Prevention Scale. 38
31310166 2019
33
A model for improving and assessing outpatient stewardship initiatives for acute respiratory infection. 38
31345276 2019
34
Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. 38
30928559 2019
35
Google Trends as a Tool for Evaluating Public Interest in Facial Cosmetic Procedures. 38
30304356 2019
36
Collaborative Solutions to Antibiotic Stewardship in Small Community and Critical Access Hospitals. 38
31274518 2019
37
Exploring the role of infection preventionists in antimicrobial stewardship programs through several lenses: A brief report. 38
31377061 2019
38
Snapshot of antimicrobial stewardship programs in the hospitals of Pakistan: findings and implications. 38
31384689 2019
39
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis. 38
30740936 2019
40
Outcomes of the PIRASOA programme, an antimicrobial stewardship programme implemented in hospitals of the Public Health System of Andalusia, Spain: an ecologic study of time-trend analysis. 38
31323260 2019
41
Implementation of Antimicrobial Stewardship Programs in End-of-Life Care. 38
31270988 2019
42
Modulation of HIF-1α/COX-2 pathway associated with attenuation of intestinal mucosa inflammatory damage by Acanthopanax senticosus polysaccharides in lipopolysaccharide-challenged piglets. 38
31177998 2019
43
Comparison of antimicrobial stewardship programmes in acute-care hospitals in four European countries: A cross-sectional survey. 38
31200022 2019
44
Status of antimicrobial stewardship programmes in Nigerian tertiary healthcare facilities: Findings and implications. 38
30557686 2019
45
Alveolar soft-part sarcoma: can MRI help discriminating from other soft-tissue tumors? A study of the French sarcoma group. 38
30560359 2019
46
A case report of alveolar soft part sarcoma demonstrating principles for uncommon vascular lesions. 38
31219648 2019
47
Personalised management of alveolar soft part sarcoma: a promising phase 2 study. 38
31078464 2019
48
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. 38
31078463 2019
49
The intervention by an antimicrobial stewardship team can improve clinical and microbiological outcomes of resistant gram-negative bacteria. 38
31255524 2019
50
Do antimicrobial stewardship programme interventions reduce the rate of and protect against Clostridium difficile infection? 38
30682564 2019

Variations for Alveolar Soft Part Sarcoma

Cosmic variations for Alveolar Soft Part Sarcoma:

9 (show all 32)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM44190 TP53 soft tissue,liver,sarcoma,NS c.359A>T p.K120M 17:7676010-7676010 15
2 COSM10667 TP53 soft tissue,liver,sarcoma,NS c.646G>A p.V216M 17:7674885-7674885 15
3 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 15
4 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 15
5 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 15
6 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 15
7 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 15
8 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 15
9 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 15
10 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 15
11 COSM487 HRAS soft tissue,neck,sarcoma,NS c.37G>A p.G13S 11:534286-534286 15
12 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 15
13 COSM1732355 H3-3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 15
14 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 15
15 COSM3908208 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 15
16 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 15
17 COSM3908209 soft tissue,bone,sarcoma,NS c.355C>T p.R119* 9:77815650-77815650 15
18 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 15
19 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 15
20 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 15
21 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 15
22 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 15
23 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 15
24 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 15
25 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 15
26 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 15
27 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 15
28 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 15
29 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 15
30 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 15
31 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 15
32 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 15

Expression for Alveolar Soft Part Sarcoma

Search GEO for disease gene expression data for Alveolar Soft Part Sarcoma.

Pathways for Alveolar Soft Part Sarcoma

Pathways related to Alveolar Soft Part Sarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Alveolar Soft Part Sarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.46 VIM TCF3 MET
2 11.19 TFE3 TCF3 MET ASPSCR1
3 11.02 TFE3 TCF3 MYOD1

GO Terms for Alveolar Soft Part Sarcoma

Cellular components related to Alveolar Soft Part Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 VIM SLC16A1 MB ENO2 ECM1 DES

Biological processes related to Alveolar Soft Part Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of myoblast differentiation GO:0045663 9.37 MYOD1 MYF6
2 positive regulation of myoblast fusion GO:1901741 9.32 MYOD1 MYF6
3 intermediate filament organization GO:0045109 9.26 VIM DES
4 positive regulation of skeletal muscle fiber development GO:0048743 9.16 MYOD1 MYF6
5 muscle cell fate commitment GO:0042693 8.96 MYOD1 MYF6
6 positive regulation of muscle cell differentiation GO:0051149 8.8 TCF3 MYOD1 MYF6

Molecular functions related to Alveolar Soft Part Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein dimerization activity GO:0046983 9.26 TFE3 TCF3 MYOD1 MYF6
2 laminin binding GO:0043236 9.16 ECM1 ADAM9
3 E-box binding GO:0070888 8.8 TCF3 MYOD1 MYF6

Sources for Alveolar Soft Part Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....